US 12,442,000 B2
Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
Monic J. Stuart, Hillsborough, CA (US); and Stephen Kelsey, Brookline, MA (US)
Assigned to Geron Corporation, Foster City, CA (US)
Filed by Geron Corporation, Parsippany, NJ (US)
Filed on Dec. 5, 2024, as Appl. No. 18/970,086.
Application 15/164,582 is a division of application No. 13/841,711, filed on Mar. 15, 2013, granted, now 9,375,485, issued on Jun. 28, 2016.
Application 18/970,086 is a continuation of application No. 17/864,129, filed on Jul. 13, 2022, abandoned.
Application 17/864,129 is a continuation of application No. 17/506,499, filed on Oct. 20, 2021, abandoned.
Application 17/506,499 is a continuation of application No. 17/229,298, filed on Apr. 13, 2021, abandoned.
Application 17/229,298 is a continuation of application No. 17/061,276, filed on Oct. 1, 2020, abandoned.
Application 17/061,276 is a continuation of application No. 16/784,931, filed on Feb. 7, 2020, abandoned.
Application 16/784,931 is a continuation of application No. 16/432,727, filed on Jun. 5, 2019, abandoned.
Application 16/432,727 is a continuation of application No. 16/141,464, filed on Sep. 25, 2018, abandoned.
Application 16/141,464 is a continuation of application No. 15/905,577, filed on Feb. 26, 2018, abandoned.
Application 15/905,577 is a continuation of application No. 15/164,582, filed on May 25, 2016, abandoned.
Claims priority of provisional application 61/734,941, filed on Dec. 7, 2012.
Prior Publication US 2025/0207136 A1, Jun. 26, 2025
Int. Cl. C12N 15/113 (2010.01); A61K 47/54 (2017.01); A61K 49/04 (2006.01); B82Y 5/00 (2011.01)
CPC C12N 15/1135 (2013.01) [A61K 47/543 (2017.08); A61K 47/549 (2017.08); A61K 49/0423 (2013.01); B82Y 5/00 (2013.01); C12N 2320/30 (2013.01)] 10 Claims
 
1. A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:
administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.